Gore clinical study adopted by NIHR Stroke Research Network

WL Gore and Associates (Gore) has welcomed news that the National Institute for Health Research (NIHR) Stroke Research Network is adopting a clinical study of one of its medical devices.

The network is offering support to the Reduce trial, which is designed to demonstrate that patent foramen ovale closure with the Gore Septal Occluder, plus antiplatelet medical management, can reduce the risk of recurrent stroke or imaging-confirmed transient ischemic attack.

It will help Gore to drive patient recruitment for the trial in England, thus aiding efforts to gather data on a potentially important new therapy for a common but serious healthcare concern.

Should the device prove to reduce stroke recurrence, it is thought it could offer major benefits to the NHS.

Dr Stuart Broyles, associate with the Gore medical division's stroke business, said: "Gore is committed to completing this study and reducing incidences of stroke. The support of the Stroke Research Network brings us one step closer to this goal."

This comes after Gore launched a clinical quality improvement study for its Gore Dualmesh Biomaterial earlier this month.